Eli Lilly and (LLY) closed at $1,416.54 on Oct 30, 2026, up 3.1% on the day. The stock is up 23.2% over the past month, up 26.3% over three months, up 32.0% year to date and up 68.3% over the past year (since Oct 30, 2025). It trades 2.3% below its 52-week high of $1,449.68 and 66.6% above its 52-week low of $850.51. The close sits above its 50-day moving average ($1,197.13) and above its 200-day moving average ($1,091.08).
NextPick tracks LLY in its GLP-1 / Obesity basket alongside NVO, HIMS, VKTX, GPCR and ALT. As of Oct 30, 2026, the basket's money-flow score is -9 (neutral), and the basket is up 4.1% over five sessions. Over the past month LLY ranks 1st of 6 basket members by price change.
Over its last 8 reports the stock moved an average of 8.1% on the first trading day after earnings, beating the options-implied move in 5 of 8.
LLY options were pricing 39% at-the-money implied volatility on Oct 23, 2026, an IV rank of 54 over the past year. Form 4 filings over the last 90 days show no open-market purchases and 3 open-market sales by insiders.
Over the last 8 reports, LLY moved an average of 8.1% on the first trading day after earnings. The move beat the options-implied move in 5 of 8 reports.
Yes — the Oct 30, 2026 close of $1,416.54 is 29.8% above the 200-day average of $1,091.08.
LLY closed 2.3% below its 52-week high of $1,449.68.
NextPick groups LLY with NVO, HIMS, VKTX, GPCR and ALT in its GLP-1 / Obesity basket.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
